Literature DB >> 12786893

HER2 oncogene amplification in extramammary Paget's disease.

M Tanskanen1, T Jahkola, S Asko-Seljavaara, J Jalkanen, J Isola.   

Abstract

AIMS: To study HER2 oncogene amplification and over-expression in skin samples of 23 patients with extramammary Paget's disease (EMP). EMP is a rare intra-epidermal adenocarcinoma, which has been reported to over-express the HER2 oncoprotein. METHODS AND
RESULTS: HER2 gene amplification, detected by chromogenic in-situ hybridization, was found in 43% (10/23) of the lesions. HER2 protein over-expression (3+ immunostaining intensity) was found in 12 tumours (52%), including all 10 tumours with gene amplification. Two tumours showed low-level (2+) HER2 immunostaining. Mammary Paget's lesions, which were used as controls, showed HER2 amplification and over-expression in all 10 cases studied.
CONCLUSIONS: These results indicate that HER-2 protein over-expression in EMP is common and due exclusively to gene amplification. They open up the possibility of HER2-targetted immunotherapy for patients with HER2+ disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12786893     DOI: 10.1046/j.1365-2559.2003.01648.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

1.  Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.

Authors:  H Awaya; Y Takeshima; O Furonaka; N Kohno; K Inai
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

Review 2.  A primer on extramammary Paget's disease for the urologist.

Authors:  Joon Yau Leong; Paul H Chung
Journal:  Transl Androl Urol       Date:  2020-02

3.  Pemetrexed induced a durable response in heavily pretreated metastatic extramammary Paget's disease.

Authors:  Chao Wu; Hai-Tao Tao; Fang-Fang Li; Shang-Wu Huang; Wei-Wei Dong; Jin-Liang Wang; Yi Hu; Fang Li
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  A Case of Metastatic Extramammary Paget's Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy.

Authors:  Fumie Hanawa; Takashi Inozume; Kazutoshi Harada; Tatsuyosi Kawamura; Naotaka Shibagaki; Shinji Shimada
Journal:  Case Rep Dermatol       Date:  2011-10-11

5.  Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.

Authors:  Peter Barth; Essel Dulaimi Al-Saleem; Kristin W Edwards; Sherri Z Millis; Yu-Ning Wong; Daniel M Geynisman
Journal:  Case Rep Oncol Med       Date:  2015-01-27

6.  Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary Paget's disease.

Authors:  Xiaolin Lu; Peipei Zhang; Yao Zhu; Dingwei Ye
Journal:  Oncol Lett       Date:  2019-01-14       Impact factor: 2.967

7.  Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A.

Authors:  Maryam Pourmaleki; Jonathan H Young; Nicholas D Socci; Sarah Chiang; Marcia Edelweiss; Yanyun Li; Mianlei Zhang; Lev Roshal; Dennis S Chi; Klaus J Busam; Ingo K Mellinghoff; Travis J Hollmann
Journal:  Oncotarget       Date:  2019-10-22

8.  The Msi1-mTOR pathway drives the pathogenesis of mammary and extramammary Paget's disease.

Authors:  Yongli Song; Christian F Guerrero-Juarez; Zhongjian Chen; Yichen Tang; Xianghui Ma; Cong Lv; Xueyun Bi; Min Deng; Lina Bu; Yuhua Tian; Ruiqi Liu; Ran Zhao; Jiuzhi Xu; Xiaole Sheng; Sujuan Du; Yeqiang Liu; Yunlu Zhu; Shi-Jun Shan; Hong-Duo Chen; Yiqiang Zhao; Guangbiao Zhou; Jianwei Shuai; Fazheng Ren; Lixiang Xue; Zhaoxia Ying; Xing Dai; Christopher J Lengner; Bogi Andersen; Maksim V Plikus; Qing Nie; Zhengquan Yu
Journal:  Cell Res       Date:  2020-05-26       Impact factor: 46.297

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.